Al-Busaidi Ibrahim S, Bailey Teresa, Dobbs Bruce, Eglinton Tim W, Wakeman Christopher J, Frizelle Frank A
Department of Surgery, Christchurch Hospital, Christchurch, New Zealand.
Department of Anatomical Pathology, Christchurch Hospital, Christchurch, New Zealand.
ANZ J Surg. 2019 Sep;89(9):1091-1096. doi: 10.1111/ans.14930. Epub 2018 Nov 28.
Ovarian metastases (OM) from colorectal cancer (CRC) are uncommon, and data about optimal management are lacking. The aim of this study was to examine the management and outcomes of patients with OM from CRC.
A retrospective review of records of patients with a histopathological diagnosis of OM from CRC who were treated at Christchurch Hospital between 1 January 2000 and 31 December 2016. Data related to presentation, clinicopathological characteristics, treatment and outcomes were recorded. The primary outcomes were overall survival and disease-free survival.
Thirty-one patients were identified (median age 55 years, range 28-77), with a median follow-up of 23 months (range 3-84 months). Abdominal pain was the most common presenting symptom (22 patients). Synchronous OM occurred in 22 patients, 14 patients had bilateral ovarian involvement. Twenty-one patients received adjuvant chemotherapy. R0 resection was achieved in 14 patients. For all patients the 5-year disease-free and overall survival were 11% and 12%, respectively, while 5-year overall survival for R0 resections was 30%. Improved median survival was associated with negative colon resection margins (26.7 months versus 7.8 months, P = 0.03), R0 resection (30.5 months versus 23.5 months, P = 0.04), and use of adjuvant chemotherapy (28.8 months versus 8.2 months, P < 0.0001); however, on multivariate analysis adjuvant chemotherapy was the only independent factor associated with improved prognosis (P = 0.01).
OM from CRC are uncommon and carry a poor prognosis. Improved survival was associated with complete surgical resection of the primary tumour and metastatic disease in combination with systemic chemotherapy.
结直肠癌(CRC)的卵巢转移(OM)并不常见,且缺乏关于最佳治疗方案的数据。本研究的目的是探讨CRC患者发生OM后的治疗及预后情况。
对2000年1月1日至2016年12月31日在克赖斯特彻奇医院接受治疗、经组织病理学诊断为CRC卵巢转移的患者记录进行回顾性分析。记录与临床表现、临床病理特征、治疗及预后相关的数据。主要结局指标为总生存期和无病生存期。
共纳入31例患者(中位年龄55岁,范围28 - 77岁),中位随访时间为23个月(范围3 - 84个月)。腹痛是最常见的首发症状(22例患者)。22例患者发生同步性OM,14例患者双侧卵巢受累。21例患者接受了辅助化疗。14例患者实现了R0切除。所有患者的5年无病生存率和总生存率分别为11%和12%,而R0切除患者的5年总生存率为30%。中位生存期的改善与结肠切除切缘阴性(26.7个月对7.8个月,P = 0.03)、R0切除(30.5个月对23.5个月,P = 0.04)以及辅助化疗的使用(28.8个月对8.2个月,P < 0.0001)相关;然而,多因素分析显示辅助化疗是与预后改善相关的唯一独立因素(P = 0.01)。
CRC的OM并不常见,预后较差。生存改善与原发肿瘤和转移灶的完整手术切除以及全身化疗有关。